Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2004 2
2005 3
2006 2
2007 4
2008 1
2009 2
2010 3
2011 7
2012 5
2013 8
2014 6
2015 10
2016 5
2017 2
2018 5
2019 12
2020 12
2021 10
2022 7
2023 7
2024 5
2025 5
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Tumor immunotargeting using innovative radionuclides.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Mathieu C, Guérard F, Frampas E, Carlier T, Chouin N, Haddad F, Chatal JF, Faivre-Chauvet A, Chérel M, Barbet J. Kraeber-Bodéré F, et al. Among authors: rousseau c. Int J Mol Sci. 2015 Feb 11;16(2):3932-54. doi: 10.3390/ijms16023932. Int J Mol Sci. 2015. PMID: 25679452 Free PMC article. Review.
Radioimmunoconjugates for the treatment of cancer.
Kraeber-Bodéré F, Bodet-Milin C, Rousseau C, Eugène T, Pallardy A, Frampas E, Carlier T, Ferrer L, Gaschet J, Davodeau F, Gestin JF, Faivre-Chauvet A, Barbet J, Chérel M. Kraeber-Bodéré F, et al. Among authors: rousseau c. Semin Oncol. 2014 Oct;41(5):613-22. doi: 10.1053/j.seminoncol.2014.07.004. Epub 2014 Jul 22. Semin Oncol. 2014. PMID: 25440606 Review.
Immuno-PET: Design options and clinical proof-of-concept.
Lugat A, Bailly C, Chérel M, Rousseau C, Kraeber-Bodéré F, Bodet-Milin C, Bourgeois M. Lugat A, et al. Among authors: rousseau c. Front Med (Lausanne). 2022 Oct 14;9:1026083. doi: 10.3389/fmed.2022.1026083. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36314010 Free PMC article. Review.
In Regard to Trotter et al.
Ah-Thiane L, Rousseau C, Supiot S. Ah-Thiane L, et al. Among authors: rousseau c. Adv Radiat Oncol. 2024 Feb 15;9(2):101410. doi: 10.1016/j.adro.2023.101410. eCollection 2024 Feb. Adv Radiat Oncol. 2024. PMID: 38405301 Free PMC article. No abstract available.
PSMA Is Not Specific to Prostate Cancer.
Ah-Thiane L, Ferrer L, Rousseau C. Ah-Thiane L, et al. Among authors: rousseau c. J Nucl Med. 2023 Aug;64(8):1326. doi: 10.2967/jnumed.123.265720. Epub 2023 Jun 22. J Nucl Med. 2023. PMID: 37348920 Free article. No abstract available.
Biopsies: next-generation biospecimens for tailoring therapy.
Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CM, Batist G. Basik M, et al. Among authors: rousseau c. Nat Rev Clin Oncol. 2013 Aug;10(8):437-50. doi: 10.1038/nrclinonc.2013.101. Epub 2013 Jun 25. Nat Rev Clin Oncol. 2013. PMID: 23799370 Review.
Prospective pilot study with [89Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE).
Rousseau C, Heyman MF, Ferrer L, Rauscher A, Morel A, Rusu D, Frenel JS, Taupin M, Vilcot L, Allam N, Robert M, Campone M, Campion L, Kraeber-Bodéré F. Rousseau C, et al. Eur J Nucl Med Mol Imaging. 2026 Mar;53(4):2403-2413. doi: 10.1007/s00259-025-07619-y. Epub 2025 Nov 1. Eur J Nucl Med Mol Imaging. 2026. PMID: 41174094 Free PMC article. Clinical Trial.
Reoxygenation during radiotherapy in intermediate-risk prostate cancer.
Supiot S, Rousseau C, Dore M, Chèze-Le-Rest C, Kandel-Aznar C, Potiron V, Guerif S, Paris F, Ferrer L, Campion L, Meingan P, Delpon G, Hatt M, Visvikis D. Supiot S, et al. Among authors: rousseau c. Radiother Oncol. 2019 Apr;133:16-19. doi: 10.1016/j.radonc.2018.12.022. Epub 2019 Jan 12. Radiother Oncol. 2019. PMID: 30935573
119 results